| Therapy with intravenous methylprednisolone pulses is associated with loss of bone microarchitecture in trabecular bone score-assessment among patients with moderate-to-severe … J Rymuza, K Pelewicz, J Przedlacki, P Miśkiewicz Frontiers in Endocrinology 13, 893600, 2022 | 8 | 2022 |
| Therapy of moderate-to-severe Graves’ orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density J Rymuza, M Popow, Z Żurecka, J Przedlacki, T Bednarczuk, P Miśkiewicz Endocrine 64, 308-315, 2019 | 8 | 2019 |
| Dysthyroid optic neuropathy: treatment with additional intravenous methylprednisolone pulses after the basic schedule is associated with stabilization or further improvement of … M Pelewicz, J Rymuza, K Pelewicz, P Miśkiewicz Journal of Clinical Medicine 11 (8), 2068, 2022 | 5 | 2022 |
| Decrease in bone formation and bone resorption during intravenous methylprednisolone pulse therapy in patients with graves’ orbitopathy J Rymuza, K Gutowska, D Kurpios-Piec, M Struga, P Miśkiewicz Journal of Clinical Medicine 11 (17), 5005, 2022 | 3 | 2022 |
| Impact of additional intravenous methylprednisolone pulse therapy on the quality of life in patients with dysthyroid optic neuropathy M Pelewicz, J Rymuza, K Pelewicz, P Miśkiewicz Journal of Medical Science 90 (2), e519-e519, 2021 | 2 | 2021 |
| High dose intravenous methylprednisolone pulse therapy causes transient increase of serum calcium and phosphate levels. J Rymuza, M Popow, T Bednarczuk, P Miśkiewicz Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 47 (279 …, 2019 | 2 | 2019 |
| Effects of tocilizumab treatment in corticosteroid-resistant graves J Rymuza, A Kuś, D Białas-Niedziela, M Turczyńska, D Kęcik, ... Endocrine Abstracts 101, 2024 | | 2024 |
| Long-term remission of corticosteroid-resistant Graves’ orbitopathy after therapy with tocilizumab J Rymuza, A Kuś, D Białas-Niedziela, M Turczyńska, D Kęcik, ... Endokrynologia Polska 75 (1), 117-118, 2024 | | 2024 |
